Advertisement

Topics

Companies Related to "Safety of Human Lactoferrin hLF1-11 for the Treatment of Infectious Complications Among Haematopoietic Stem Cell Transplant Recipients" [Most Relevant Company Matches] RSS

11:45 EST 19th February 2019 | BioPortfolio

Here are the most relevant search results for "Safety of Human Lactoferrin hLF1-11 for the Treatment of Infectious Complications Among Haematopoietic Stem Cell Transplant Recipients" found in our extensive corporate database of over 50,000 company records.

Showing "Safety Human Lactoferrin hLF1 Treatment Infectious Complications Among" Companies 1–25 of 6,600+

Relevant

Agennix Incorporated

Agennix is developing this technology through the prototype stage in each application area. Prototype development includes overseeing the production of recombinant human lactoferrin, safety and toxicity studies and preclinical efficacy studies.


Aethlon Medical, Inc

Aethlon Medical is a publicly traded company based in San Diego, California. Since June of 2001, the sole focus of the company has been the development of a broad spectrum viral and toxin treatment device known as Hemopurifier™. During this period, Aethlon researchers have evolved the Hemopurifier from a conceptual device to a product now being manufactured and tested for safety in human clinica...

LionexDiagnostics & Therapeutics GmbH

Lionex is a biotech company dedicated to modern biomedicine for human health. Considering the revolutionary pace at which human and microbial genomic sequence information is progressing, it is becoming clear that rapid progress will also be made in future in identifying and developing new targets and drugs for the treatment of various infectious and non-infectious human diseases. Lionex is develop...


Elusys Therapeutics, Inc

Elusys Therapeutics, Inc. is a privately-held biopharmaceutical company focused on the development of targeted anti-infective therapeutics using proprietary Heteropolymer (HP) Antibodies for the treatment of infectious disease. The Company’s most advanced product, Anthim™, a treatment for Anthrax infection, has entered Phase I human safety studies. Anthim represents a near-term revenue opportu...

IQ Therapeutics BV

IQ Therapeutics BV is a human antibody technology company based in Groningen, The Netherlands. Its mission is to develop instant immunity for healthcare threats, through the development its Instant Immunity(TM) for therapeutic applications in biodefense, infectious diseases and oncology. The company is applying its Cloning the Human Response(TM) technology for its pipeline and third parties' t...

ImmuCell

ImmuCell Corporation is a biotechnology company engaged in the development of animal health products to expand its commercialized line of products for use by dairy and beef producers. The Company is also conducting a Phase II clinical trial of DiffGAM{TM} bovine anti-CLOSTRIDIUM DIFFICILE immunoglobulins, a human application of its milk-derived passive antibody technology, for use as an alternati...

National Center for Genome Resources

The National Center for Genome Resources (NCGR) in Santa Fe, New Mexico, is a non-profit research institution dedicated to improving human health and nutrition through collaborative research at the intersection of bioscience, computing and mathematics. Our vision is to pioneer the use of software and computation to improve treatment of diseases and nutrition.At NCGR we study the influence of genet...

Acceptys, Inc.

Acceptys is a private biotechnology company focused on the development of human antibody therapies in cancer and infectious diseases. The Company's key strength is its ability to directly leverage the power of the human immune system, which has continually evolved with the specific purpose of preserving health. More specifically, Acceptys can capture thousands of antibodies from strategically targ...

The Center for Infectious Disease Research

The Center for Infectious Disease Research is the largest independent, nonprofit organization in the U.S. focused solely on infectious disease research. Our mission is to make transformative scientific advancements that lead to the prevention and treatment of infectious diseases. We advance the science to develop vaccines, drugs, and diagnostics for infect...

Center for Infectious Disease Research

Center for Infectious Disease Research is the largest independent, non-profit organization in the U.S. focused solely on infectious disease research. Our mission is to make transformative scientific advancements that lead to the prevention and treatment of infectious diseases. We advance the science to develop vaccines, drugs, and diagnostics for infectiou...

Geovax Labs

GeoVax is a Biotechnology company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus - AIDS) and other infectious agents. Our goals include: developing AIDS vaccines for global markets, manufacturing and testing these vaccines under GMP/GLP conditions (FDA guidelines), conducting phase I/II and III human trials for vaccine safety and effectiveness and obtaining r...

Accelerator Corp

VieVax Corp. is focused on commercializing a novel approach to vaccine development that is designed to overcome the limitations of existing vaccine technologies. These technologies, largely unchanged and unimproved for the past half-century, have consistently fallen short in addressing a number of critical issues, including: the spread of serious emerging infectious diseases, the emergence of trea...

National Foundation for Infectious Diseases (NFID)

The National Foundation for Infectious Diseases (NFID) is a non-profit, tax-exempt (501c3) organization founded in 1973 and dedicated to educating the public and healthcare professionals about the causes, treatment, and prevention of infectious diseases.

VaxGen Inc.

VaxGen Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of biologic products for the prevention and treatment of human infectious disease. Founded in 1995, VaxGen’s business strategy emphasizes the development and commercialization of vaccine candidates for the prevention of potential bioterrorism threats, specifically anthrax and smallpox. Our lo...

Potenza Therapeutics, Inc.

Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. Astellas has approximately 17,000 employees worldwide. The organization is committed to becoming a global category leader in Urology, Immunology (including ...

PuriCore plc

PuriCore plc (LSE:PURI) is a water-based clean technology company focused on developing and commercializing proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore’s patented, proprietary technology mimics the human body’s production of the nat...

AlphaVax, Inc

AlphaVax is developing a new vaccine technology with broad applications against infectious disease, cancer and biodefense threats which has the potential to redefine vaccines and the role they play in medicine. AlphaVax uses a specialized viral vector system to make alphavirus replicon vaccines called alphavaccines, which have shown excellent protection in multiple models for infectious disease an...

GeoVax Labs, Inc.

GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus - that leads to AIDS) and other infectious agents. Our goals include developing HIV/AIDS vaccines for global markets, manufacturing and testing these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining re...

Zelos Therapeutics Inc.

Zelos Therapeutics is an emerging private biopharmaceutical development company that is commercializing breakthrough discoveries in parathyroid hormone (PTH) research. The company is developing medications for the treatment of osteoporosis, psoriasis and for enhancing engraftment following stem cell transplantation. During 2005, Zelos Therapeutics experienced a number of significant milestones. Ke...

BioChem Pharma Incorporated

BioChem Pharma Inc. (BioChem) is an international biopharmaceutical company dedicated to the research, development and commercialization of innovative products mainly for the prevention and treatment of human diseases, with a focus in cancer and infectious diseases.

Theraclone Sciences, Inc.

Theraclone Sciences is a Seattle‐based biotechnology company focused on the development of novel therapeutic antibodies for the treatment of infectious disease and cancer. The company’s technology harnesses the power of the human immune system to identify rare, naturally evolved antibodies from the blood cells of immunologically relevant human su...

Intralytix, Inc.

lntralytix was founded in 1998 to address growing problems in the control and treatment of disease-causing bacteria. These problems are presently compounded by public and governmental reluctance to employ new and potentially hazardous chemical agents or solutions born of recombinant technology. Intralytix is using its core bacteriophage technology to develop novel natural products for use in food ...

Theraclone Sciences

Theraclone Sciences is a Seattle‐based biotechnology company focused on the development of novel therapeutic antibodies for the treatment of infectious disease and cancer. The company’s technology harnesses the power of the human immune system to identify rare, naturally evolved antibodies from the blood cells of immunologically relevant human su...

Boston Biomedica Incorporated

Boston Biomedica, Inc. is an infectious diseases management company providing products and services for the detection and treatment of infectious diseases (ID) such as AIDS, Lyme Disease, and Viral Hepatitis.

Genmab Inc.

Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. At present, Genmab has multiple par...


More From BioPortfolio on "Safety of Human Lactoferrin hLF1-11 for the Treatment of Infectious Complications Among Haematopoietic Stem Cell Transplant Recipients"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks